Anthony S. Fauci, MD returns to JAMA’s Q&A series to discuss the latest developments in the COVID-19 pandemic, including the continued importance of nonpharmaceutical interventions (masking, handwashing, physical distancing) for managing rising case numbers in the US and globally.
Recorded October 28, 2020.
Topics discussed in this interview: 0:00 Introduction 0:20 NAM Presidential Citation for Exemplary Leadership 1:19 COVID-19 numbers and excess deaths 4:05 National masking mandate 5:55 How to get people to accept masking 7:07 Herd Immunity and the Great Barrington Declaration 9:51 The holidays and airplane travel 13:44 Therapies update 17:54 Vaccines update 20:08 Vaccine distribution 22:00 Vaccine safety 24:42 How Australia has dealt with COVID-19 spikes 27:00 Acknowledgements and baseball
The 65-year old American chef Thomas Keller discusses his latest book, “The French Laundry, Per Se”. The restaurateur also discusses how his company has fared during the coronavirus pandemic.
Thomas Keller is an American chef, restaurateur, and cookbook writer. He and his landmark Napa Valley restaurant, The French Laundry in Yountville, California, have won multiple awards from the James Beard Foundation, notably the Best California Chef in 1996, and the Best Chef in America in 1997.
About 90% of the Duck Inn’s current revenue comes from customers enjoying socially distant table service in their outdoor seating area. Especially in places like Chicago where temperatures drop below freezing, it’s one of many restaurants grappling with how to prepare for and survive winter.
It’s one of the tiniest machines on the planet — about a hundred times smaller than the average cell. It’s so small that no scientist can spot it through a typical light microscope. Only with an electron microscope can we see its spiky surface. It’s not alive, and it’s not what most of us would think of as “dead.” This teensy machine seems to survive in a kind of purgatory state, yet it has traveled across continents and oceans from host to host, and brought hundreds of nations to a standstill. Despite its diminutive size, the novel coronavirus, dubbed SARS-CoV-2, has seemingly taken the world by surprise with its virulence.
We take a look back over the past six months of the pandemic, and discuss how far the world has come. It’s been a period of turmoil and science has faced an unprecedented challenge. What lessons can be learned from the epidemic so far to continue the fight in the months to come?
Also in this episode:
12:55 Unanswered questions
After months of intensive research, much is known about the new coronavirus – but many important questions remain unanswered. We look at the knowledge gaps researchers are trying to fill.
The inability to travel during lockdown has seriously hampered many researchers’ ability to gather fieldwork data. We hear from three whose work has been affected, and what this means for their projects.
President Trump’s preferred coronavirus treatment is the focus of a new study suggesting it could cause more harm than good, but not everybody agrees. We discuss the fallout as trials around the world are paused and countries diverge over policy advice.
12:12 Are we rushing science?
Coronavirus papers are being published extremely quickly, while normally healthy scientific debate is being blown up in the world’s press. Is there a balancing act between timely research and accurate messaging?
18:49 One good thing
Our hosts pick out things that have made them smile in the last week, including hedgerow brews and a trip into the past using AI.
Interview with Dr. Nicole Lurie on rapid vaccine development, including new tools to facilitate vaccine testing and manufacturing and persistent challenges.
The need to rapidly develop a vaccine against SARS-CoV-2 comes at a time of explosion in basic scientific understanding, including in areas such as genomics and structural biology, that is supporting a new era in vaccine development. Over the past decade, the scientific community and the vaccine industry have been asked to respond urgently to epidemics of H1N1 influenza, Ebola, Zika, and now SARS-CoV-2. An H1N1 influenza vaccine was developed relatively rapidly, largely because influenza-vaccine technology was well developed and key regulators had previously decided that vaccines made using egg- and cell-based platforms could be licensed under the rules used for a strain change. Although a monovalent H1N1 vaccine was not available before the pandemic peaked in the Northern Hemisphere, it was available soon afterward as a stand-alone vaccine and was ultimately incorporated into commercially available seasonal influenza vaccines.
Nicole Lurie is a strategic advisor to the CEO of the Coalition for Epidemic Preparedness Innovations. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal.
Online News Editor David Grimm talks with producer Joel Goldberg about the unique challenges of reopening labs amid the coronavirus pandemic. Though the chance to resume research may instill a sense of hope, new policies around physical distancing and access to facilities threaten to derail studies—and even careers.
Despite all the uncertainty, the crisis could result in new approaches that ultimately benefit the scientific community and the world. Also this week, Joel Podgorski, a senior scientist in the Water Resources and Drinking Water Department at the Swiss Federal Institute of Aquatic Science and Technology, joins host Sarah Crespi to discuss the global threat of arsenic in drinking water. Arsenic is basically present in all rocks in minute amounts. Under the right conditions it can leach into groundwater and poison drinking water. Without a noticeable taste or smell, arsenic contamination can go undetected for years. The paper, published in Science, estimates that more than 100 million people are at risk of drinking arsenic-contaminated water and provides a guide for the most important places to test.
Predicting the path ahead has become nearly impossible, but we can speculate about the size and scale of the economic shock. Economic contagion is now spreading as fast as Covid-19 itself. Social distancing, intended to physically disrupt the spread, has severed the flow of goods and people, stalled economies, and is in the process of delivering a global recession.
Predicting the path ahead has become nearly impossible, as multiple dimensions of the crisis are unprecedented and unknowable. Pressing questions include the path of the shock and recovery, whether economies will be able to return to their pre-shock output levels and growth rates, and whether there will be any structural legacy from the coronavirus crisis.
This Explainer explores several scenarios to model the size and scale of the economic shock and the path ahead.
Based on the HBR article by Philipp Carlsson-Szlezak, Martin Reeves and Paul Swartz